West Pharmaceutical Services (NYSE:WST) declared that its board has authorized a stock repurchase plan, which allows the company to buyback 800,000 outstanding shares on Thursday, February 15th, EventVestor reports. This buyback authorization allows the medical instruments supplier to purchase shares of its stock through open market purchases. Shares buyback plans are typically a sign that the company’s management believes its shares are undervalued.
WST has been the topic of several recent analyst reports. Zacks Investment Research raised West Pharmaceutical Services from a “sell” rating to a “hold” rating in a research report on Friday, January 26th. Wells Fargo & Co upped their price target on West Pharmaceutical Services from $105.00 to $112.00 and gave the company an “outperform” rating in a research report on Friday, October 27th. Finally, Goldman Sachs Group initiated coverage on West Pharmaceutical Services in a research report on Wednesday, January 24th. They set a “neutral” rating and a $110.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the stock. West Pharmaceutical Services has an average rating of “Hold” and an average target price of $108.17.
West Pharmaceutical Services (WST) opened at $87.45 on Friday. The company has a debt-to-equity ratio of 0.15, a current ratio of 2.59 and a quick ratio of 1.87. West Pharmaceutical Services has a 52 week low of $77.97 and a 52 week high of $103.36. The company has a market capitalization of $6,559.50, a PE ratio of 43.94, a price-to-earnings-growth ratio of 1.87 and a beta of 1.04.
The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 2nd. Shareholders of record on Wednesday, April 18th will be paid a $0.14 dividend. The ex-dividend date is Tuesday, April 17th. This represents a $0.56 dividend on an annualized basis and a yield of 0.64%. West Pharmaceutical Services’s dividend payout ratio (DPR) is currently 28.14%.
In other West Pharmaceutical Services news, CFO William J. Federici sold 21,000 shares of the business’s stock in a transaction dated Friday, December 8th. The stock was sold at an average price of $99.01, for a total value of $2,079,210.00. Following the transaction, the chief financial officer now owns 190,493 shares in the company, valued at $18,860,711.93. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.90% of the company’s stock.
WARNING: This news story was posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at https://www.chaffeybreeze.com/2018/02/18/share-repurchase-plan-initiated-by-west-pharmaceutical-services-wst.html.
About West Pharmaceutical Services
West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.